Pamidronate disodium Injection Rx

Select the drug indication to add to your list

Pamidronate disodium Injection

Bone disorders
Breast cancer
Cytoprotective and supportive care agents
Leukemias, lymphomas, and other hematologic cancers
Only 4 drugs may be compared at once

Generic Name and Formulations:

Pamidronate disodium 30mg, 90mg; per vial; pwd for IV infusion after reconstitution; contains mannitol.

Select therapeutic use:

Indications for Pamidronate disodium Injection:

Paget's disease.

Adult:

Give by IV infusion. 30mg daily infused over 4hrs on 3 consecutive days for a total of 90mg.

Children:

Not recommended.

Warnings/Precautions:

Severe renal impairment in patients with bone metastases: not recommended. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases 0.5mg/dL from normal pre-treatment levels, or by 1mg/dL from an abnormal pre-treatment level. Monitor electrolytes (esp. calcium, magnesium, phosphate, potassium), CBC/differential, hematocrit/hemoglobin. Pre-existing blood disorders (eg, anemia, leukopenia, thrombocytopenia); monitor closely for first 2 weeks after treatment. Avoid dental surgery (do preventative dental work before therapy). Evaluate if thigh or groin pain develops and consider discontinuing if atypical femur fracture is suspected. Pregnancy (Cat.D): not recommended. Nursing mothers.

Interactions:

Caution with other nephrotoxic drugs (eg, thalidomide).

Pharmacological Class:

Bisphosphonate.

Adverse Reactions:

Infusion-site reactions, fever, headache, dizziness, paresthesia, increased sweating, GI upset, anemia, fatigue, musculoskeletal pain (may be severe), electrolyte disturbances, hypertension, dyspnea, renal toxicity; jaw osteonecrosis, atypical subtrochanteric and diaphyseal femoral fractures.

How Supplied:

Contact supplier.

Indications for Pamidronate disodium Injection:

Osteolytic bone metastases of breast cancer.

Adult:

Give by IV infusion. 90mg infused over 2hrs every 3–4wks. Max single dose: 90mg.

Children:

Not recommended.

Warnings/Precautions:

Severe renal impairment in patients with bone metastases: not recommended. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases 0.5mg/dL from normal pre-treatment levels, or by 1mg/dL from an abnormal pre-treatment level. Monitor electrolytes (esp. calcium, magnesium, phosphate, potassium), CBC/differential, hematocrit/hemoglobin. Pre-existing blood disorders (eg, anemia, leukopenia, thrombocytopenia); monitor closely for first 2 weeks after treatment. Avoid dental surgery (do preventative dental work before therapy). Evaluate if thigh or groin pain develops and consider discontinuing if atypical femur fracture is suspected. Pregnancy (Cat.D): not recommended. Nursing mothers.

Interactions:

Caution with other nephrotoxic drugs (eg, thalidomide).

Pharmacological Class:

Bisphosphonate.

Adverse Reactions:

Infusion-site reactions, fever, headache, dizziness, paresthesia, increased sweating, GI upset, anemia, fatigue, musculoskeletal pain (may be severe), electrolyte disturbances, hypertension, dyspnea, renal toxicity; jaw osteonecrosis, atypical subtrochanteric and diaphyseal femoral fractures.

How Supplied:

Contact supplier.

Indications for Pamidronate disodium Injection:

Hypercalcemia of malignancy.

Adult:

Give by IV infusion. Assure adequate hydration; give as a single dose infused over 2–24hrs; moderate disease (albumin-corrected serum calcium 12–13.5mg/dL): 60–90mg; severe disease (albumin-corrected serum calcium >13.5mg/dL): 90mg; allow at least 7 days before retreating. Max single dose: 90mg.

Children:

Not recommended.

Warnings/Precautions:

Severe renal impairment in patients with bone metastases: not recommended. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases 0.5mg/dL from normal pre-treatment levels, or by 1mg/dL from an abnormal pre-treatment level. Monitor electrolytes (esp. calcium, magnesium, phosphate, potassium), CBC/differential, hematocrit/hemoglobin. Pre-existing blood disorders (eg, anemia, leukopenia, thrombocytopenia); monitor closely for first 2 weeks after treatment. Avoid dental surgery (do preventative dental work before therapy). Evaluate if thigh or groin pain develops and consider discontinuing if atypical femur fracture is suspected. Pregnancy (Cat.D): not recommended. Nursing mothers.

Interactions:

Caution with other nephrotoxic drugs (eg, thalidomide).

Pharmacological Class:

Bisphosphonate.

Adverse Reactions:

Infusion-site reactions, fever, headache, dizziness, paresthesia, increased sweating, GI upset, anemia, fatigue, musculoskeletal pain (may be severe), electrolyte disturbances, hypertension, dyspnea, renal toxicity; jaw osteonecrosis, atypical subtrochanteric and diaphyseal femoral fractures.

How Supplied:

Contact supplier.

Indications for Pamidronate disodium Injection:

Osteolytic lesions of multiple myeloma.

Adult:

Give by IV infusion. 90mg infused over 4hrs once monthly. Max single dose: 90mg.

Children:

Not recommended.

Warnings/Precautions:

Severe renal impairment in patients with bone metastases: not recommended. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases 0.5mg/dL from normal pre-treatment levels, or by 1mg/dL from an abnormal pre-treatment level. Monitor electrolytes (esp. calcium, magnesium, phosphate, potassium), CBC/differential, hematocrit/hemoglobin. Pre-existing blood disorders (eg, anemia, leukopenia, thrombocytopenia); monitor closely for first 2 weeks after treatment. Avoid dental surgery (do preventative dental work before therapy). Evaluate if thigh or groin pain develops and consider discontinuing if atypical femur fracture is suspected. Pregnancy (Cat.D): not recommended. Nursing mothers.

Interactions:

Caution with other nephrotoxic drugs (eg, thalidomide).

Pharmacological Class:

Bisphosphonate.

Adverse Reactions:

Infusion-site reactions, fever, headache, dizziness, paresthesia, increased sweating, GI upset, anemia, fatigue, musculoskeletal pain (may be severe), electrolyte disturbances, hypertension, dyspnea, renal toxicity; jaw osteonecrosis, atypical subtrochanteric and diaphyseal femoral fractures.

How Supplied:

Contact supplier.